Bio-Works Technologies (BIOWKS.ST) Stock Analysis & AI Equity Report
Bio-Works Technologies (BIOWKS.ST) overview
Bio-Works Technologies (BIOWKS.ST) stock analysis and AI equity research. For the latest completed financial year, 2025, Bio-Works Technologies reported revenue of SEK 62.5m and operating profit of SEK -17.5m; the year-end share price was 2.62 SEK and market capitalisation was SEK 228m. Bio-Works Technologies is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Bio-Works Technologies's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-07-27. Data will be refreshed during report generation.
About Bio-Works Technologies
Bio-Works Technologies develops and sells agarose-based chromatography resins and pre-packed columns for purification of biomolecules. Its WorkBeads products are used in research, process development and manufacturing to separate antibodies, proteins, peptides, oligos, viruses and vaccines. The company also offers related purification formats and serves the biopharmaceutical and broader life science industries.
Generate the Bio-Works Technologies report
Bio-Works Technologies is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Bio-Works Technologies and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Bio-Works Technologies
Each is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by what other analysts said the work added over the engine's report — a score out of five from people who had to read it to give it.